ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2172

An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs

Susan Knowles1, Dominick Sudano1, Sara Taroumian2, Neil M. Ampel3, John Galgiani4, Jeffrey R. Lisse1 and Susan E. Hoover5, 1Department of Rheumatology, University of Arizona, Tucson, AZ, 2Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 3Infectious Disease, University of Arizona, Tucson, AZ, 4Valley Fever Center for Excellence, Tucson, AZ, 5Infectious Diseases, University of Arizona, Tucson, AZ

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: biologic response modifiers, DMARDs, infection and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease on immunosuppressive medication, including methotrexate and tumor necrosis factor (TNF) antagonists, are at higher risk of more severe infection or dissemination. Currently, there are no guidelines for management of coccidioidomycosis in patients on disease-modifying antirheumatic drug (DMARD) or biologic response modifier (BRM) therapy.

Methods: A retrospective chart review identified patients at two centers in Tucson, Arizona, who developed coccidioidomycosis while on DMARD or BRM therapy. Review emphasized disease manifestations, antifungal therapy and duration, as well as management of BRM/DMARD therapy.

Results: Sixty-six patients who developed coccidioidomycosis while on DMARD and/or BRM therapy were identified.  Forty-four of these have been previously reported, and their charts were re-reviewed for an additional 12 months of follow-up. Twenty-two new patients were identified. Rheumatologic treatment included BRM alone (18), DMARD alone (15), or combination therapy (33). Eighteen patients were on oral prednisone at the time of diagnosis, with doses ranging from 3 to 40 mg daily (median 10 mg). Manifestations of coccidioidomycosis were asymptomatic positive serologies (15), pulmonary illness (41), and dissemination (10). At the time of coccidioidomycosis diagnosis, 35 patients held all BRM and DMARD therapy, 9 patients held BRM but continued DMARD therapy, and 22 patients had no change in immunosuppressive therapy. Most patients (54) received antifungal therapy, usually for 3 months or longer.

Follow-up data were available for 56 patients. BRM and/or DMARD therapy was continued or resumed in 45 patients, of whom 17 continued concurrent antifungal therapy. Three patients with disseminated disease restarted BRM therapy. The most common reasons for continuing antifungal therapy were persistent positive serology or disseminated disease. The most common reason for stopping antifungal therapy was a negative serology. Follow-up for patients who stopped antifungal therapy or were never treated is 2 to 119 months (median 18 mos). One patient on DMARD and corticosteroid therapy died soon after diagnosis of severe disseminated coccidioidomycosis despite antifungal therapy. Another patient with coccidioidal meningitis had relapse of disease, possibly related to non-adherence to antifungal therapy. Otherwise, there have been no cases of subsequent dissemination or complications to date.

Conclusion: Continuing or restarting DMARD and/or BRM therapy after coccidioidomycosis appears to be safe in some patients with appropriate monitoring. If coccidioidomycosis is asymptomatic and rheumatic disease is active, continuation of DMARD and/or BRM can be considered. Patients with symptomatic infection should stop immunosuppressive therapy and continue antifungal therapy until the coccidioidomycosis is under control.


Disclosure:

S. Knowles,
None;

D. Sudano,
None;

S. Taroumian,
None;

N. M. Ampel,
None;

J. Galgiani,

Valley Fever Solutions, Inc,

4;

J. R. Lisse,
None;

S. E. Hoover,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-update-of-management-of-coccidioidomycosis-in-patients-on-biologic-response-modifiers-and-disease-modifying-antirheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology